Diabetes Drug Could Cause Pancreatic Cancer

Email this article to a friend

Printable Version

Articles Related to This Article: • American Diabetes Association peddling nutritional nonsense while accepting money from manufacturer of candy and sodas • Chemical Causes of Diabetes: Overeating Is Not the Only Problem • Chromium prevents diabetes by improving insulin sensitivity Support NaturalNews advertisers - Advertise with NaturalNews Help support NaturalNews with health books and educational programs from Truth Publishing: • Swine Flu Advanced Preparedness • 8 Weeks to Vibrant Health • Raw In Ten Minutes (recipes) • How to Halt Diabetes in 25 Days ... and much more.

(NaturalNews) The popular diabetes drug sitagliptin (marketed as Januvia) may increase the risk of pancreatic cancer, according to study conducted by researchers from the University of California-Los Angeles and published in the journal Diabetes.

"Type 2 diabetes is a lifelong disease -- people often take the same drugs for many years, so any adverse effect that could over time increase the risk for pancreatic cancer would be a concern," said lead researcher Peter Butler. "A concern here is that the unwanted effects of this drug on the pancreas would likely not be detected in humans unless the pancreas was removed and examined."

Previous research has suggested that the diabetes drug Byetta might increase the risk of pancreatic inflammation (pancreatitis), a known risk factor for pancreatic cancer. Byetta and Januvia both act by enhancing the activity of a gut hormone known as glucagon-like-peptide-1 (GLP-1), thereby resulting in lower blood sugar.

Byetta manufacturer Amylin Corp. has insisted that the connection between Byetta and pancreatitis could be coincidence, since no mechanism to explain the correlation has yet been found. The new study suggests, however, that enhanced GLP-1 activity might itself be a risk factor for pancreatitis.

Researchers conducted the study on rats that had been genetically engineered to simulate the metabolism of humans with Type 2 diabetes, as well as their Islets of Langerhans. They treated 40 rats with either Januvia or a Januvia-metformin combination for 12 weeks.

The Islets of Langerhans are hormone-producing regions of the pancreas. Metformin is an older diabetes drug that is believed to have tumor-suppressing properties.

The researchers found that rats treated only with Januvia had significantly higher proliferation of beta cells in their Islets of Langerhans, while some developed pancreatic abnormalities or inflammation. Rats treated with both drugs did not exhibit this effect.

Beta cells produce the blood sugar-regulating hormone insulin.

Sources for this story include: www.upi.com; www.sciencecentric.com.

Share

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • American Diabetes Association peddling nutritional nonsense while accepting money from manufacturer of candy and sodas • Chemical Causes of Diabetes: Overeating Is Not the Only Problem • Chromium prevents diabetes by improving insulin sensitivity	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/027115_diabetes_Januvia_pancreas.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/027115_diabetes_Januvia_pancreas.html">Diabetes Drug Could Cause Pancreatic Cancer</a>